ES2798119T3 - Método para evaluar un inmunorrepertorio - Google Patents
Método para evaluar un inmunorrepertorio Download PDFInfo
- Publication number
- ES2798119T3 ES2798119T3 ES14749095T ES14749095T ES2798119T3 ES 2798119 T3 ES2798119 T3 ES 2798119T3 ES 14749095 T ES14749095 T ES 14749095T ES 14749095 T ES14749095 T ES 14749095T ES 2798119 T3 ES2798119 T3 ES 2798119T3
- Authority
- ES
- Spain
- Prior art keywords
- immunoprofile
- subject
- sequences
- library
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 74
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 99
- 201000010099 disease Diseases 0.000 claims abstract description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 96
- 241000282414 Homo sapiens Species 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 230000001186 cumulative effect Effects 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 60
- 230000003321 amplification Effects 0.000 claims description 51
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 44
- 238000012163 sequencing technique Methods 0.000 claims description 40
- 230000008707 rearrangement Effects 0.000 claims description 35
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 33
- 108091093088 Amplicon Proteins 0.000 claims description 26
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 26
- 210000000265 leukocyte Anatomy 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 210000003519 mature b lymphocyte Anatomy 0.000 claims description 3
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 3
- 210000004296 naive t lymphocyte Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 30
- 239000000523 sample Substances 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108091008874 T cell receptors Proteins 0.000 description 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 206010003805 Autism Diseases 0.000 description 5
- 208000020706 Autistic disease Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000007403 mPCR Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000011325 microbead Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011219 Costochondritis Diseases 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000772111 Homo sapiens T cell receptor alpha variable 2 Proteins 0.000 description 1
- 101000794417 Homo sapiens T cell receptor alpha variable 3 Proteins 0.000 description 1
- 101000794420 Homo sapiens T cell receptor alpha variable 4 Proteins 0.000 description 1
- 101000794371 Homo sapiens T cell receptor alpha variable 5 Proteins 0.000 description 1
- 241000722343 Human papillomavirus types Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 108700015679 Nested Genes Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102100029486 T cell receptor alpha variable 2 Human genes 0.000 description 1
- 102100030199 T cell receptor alpha variable 3 Human genes 0.000 description 1
- 102100030196 T cell receptor alpha variable 4 Human genes 0.000 description 1
- 102100030178 T cell receptor alpha variable 5 Human genes 0.000 description 1
- 208000026317 Tietze syndrome Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008709 cellular rearrangement Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/30—Data warehousing; Computing architectures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Computing Systems (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Library & Information Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763451P | 2013-02-11 | 2013-02-11 | |
| PCT/US2014/015841 WO2014124451A1 (en) | 2013-02-11 | 2014-02-11 | Method for evaluating an immunorepertoire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2798119T3 true ES2798119T3 (es) | 2020-12-09 |
Family
ID=51300201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14749095T Active ES2798119T3 (es) | 2013-02-11 | 2014-02-11 | Método para evaluar un inmunorrepertorio |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160034637A1 (enExample) |
| EP (1) | EP2954070B1 (enExample) |
| JP (1) | JP6460343B2 (enExample) |
| KR (1) | KR102228488B1 (enExample) |
| CN (1) | CN105164277B (enExample) |
| CA (1) | CA2900776C (enExample) |
| ES (1) | ES2798119T3 (enExample) |
| PT (1) | PT2954070T (enExample) |
| WO (1) | WO2014124451A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144776A1 (en) * | 2015-03-06 | 2016-09-15 | Cb Biotechnologies, Inc. | Method for measuring a change in an individual's immunorepertoire |
| US20160333409A1 (en) * | 2015-03-09 | 2016-11-17 | Cb Biotechnologies, Inc. | Method for identifying disease-associated cdr3 patterns in an immune repertoire |
| US11047011B2 (en) * | 2015-09-29 | 2021-06-29 | iRepertoire, Inc. | Immunorepertoire normality assessment method and its use |
| WO2017193097A1 (en) | 2016-05-06 | 2017-11-09 | Girihlet Inc. | Methods and compositions for determining specifc tcr and bcr chain pairings |
| CN106283201B (zh) * | 2016-09-20 | 2019-08-06 | 中国医学科学院肿瘤医院 | 基于高通量测序的tcr多样性检测和文库构建 |
| US20200199650A1 (en) * | 2017-05-18 | 2020-06-25 | Geneplus－Beijing | Analysis system for peripheral blood-based non-invasive detection of lesion immune repertoire diversity and uses of system |
| WO2019046817A1 (en) * | 2017-09-01 | 2019-03-07 | Life Technologies Corporation | COMPOSITIONS AND METHODS FOR IMMUNOLOGICAL REPERTOIRE SEQUENCING |
| EP3824103A1 (en) | 2018-07-18 | 2021-05-26 | Life Technologies Corporation | Compositions and methods for immune repertoire sequencing |
| WO2020236745A1 (en) * | 2019-05-17 | 2020-11-26 | iRepertoire, Inc. | Immunorepertoire wellness assessment systems and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2257152C (en) * | 1996-06-03 | 2009-01-27 | Linda M. Pilarski | Methods for detection of rearranged dna |
| CN107385040B (zh) | 2008-04-03 | 2022-02-15 | 艾瑞普特公司 | 用于扩增多个靶标的扩增子拯救多重聚合酶链式反应 |
| CN102066578B (zh) * | 2008-04-16 | 2016-07-06 | 哈森阿尔法生物技术研究院 | 用于评价和比较免疫组库的方法 |
| GB2483810B (en) * | 2008-11-07 | 2012-09-05 | Sequenta Inc | Methods for correlating clonotypes with diseases in a population |
| US8691510B2 (en) * | 2008-11-07 | 2014-04-08 | Sequenta, Inc. | Sequence analysis of complex amplicons |
| EP3456847B1 (en) | 2010-05-06 | 2024-12-25 | Adaptive Biotechnologies Corporation | Monitoring solid transplant rejection using clonotype profiles |
| CA2796822C (en) * | 2010-05-07 | 2021-10-05 | The Board Of Trustees Of The Leland Standford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
| US20120183969A1 (en) | 2011-01-14 | 2012-07-19 | Jian Han | Immunodiversity Assessment Method and Its Use |
| KR20200003235A (ko) * | 2011-09-28 | 2020-01-08 | 씨비 바이오테크놀로지스, 인크. | arm-PCR 및 고속 처리 서열 분석을 이용한 항원 특이적 후천성 면역 반응의 확인 |
| CN106103711A (zh) * | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
-
2014
- 2014-02-11 US US14/767,178 patent/US20160034637A1/en not_active Abandoned
- 2014-02-11 KR KR1020157023530A patent/KR102228488B1/ko active Active
- 2014-02-11 CN CN201480020810.1A patent/CN105164277B/zh active Active
- 2014-02-11 CA CA2900776A patent/CA2900776C/en active Active
- 2014-02-11 JP JP2015557201A patent/JP6460343B2/ja active Active
- 2014-02-11 PT PT147490957T patent/PT2954070T/pt unknown
- 2014-02-11 EP EP14749095.7A patent/EP2954070B1/en active Active
- 2014-02-11 ES ES14749095T patent/ES2798119T3/es active Active
- 2014-02-11 WO PCT/US2014/015841 patent/WO2014124451A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20160034637A1 (en) | 2016-02-04 |
| HK1212735A1 (zh) | 2016-06-17 |
| CA2900776C (en) | 2023-08-15 |
| EP2954070A1 (en) | 2015-12-16 |
| CN105164277B (zh) | 2021-05-28 |
| JP6460343B2 (ja) | 2019-01-30 |
| KR102228488B1 (ko) | 2021-03-15 |
| KR20150141939A (ko) | 2015-12-21 |
| JP2016506750A (ja) | 2016-03-07 |
| EP2954070A4 (en) | 2016-10-26 |
| CA2900776A1 (en) | 2014-08-14 |
| EP2954070B1 (en) | 2020-04-01 |
| PT2954070T (pt) | 2020-06-22 |
| CN105164277A (zh) | 2015-12-16 |
| WO2014124451A1 (en) | 2014-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2798119T3 (es) | Método para evaluar un inmunorrepertorio | |
| Rodriguez et al. | Genetic variation in the immunoglobulin heavy chain locus shapes the human antibody repertoire | |
| AU2009244634B2 (en) | Method for evaluating and comparing immunorepertoires | |
| US20170335386A1 (en) | Method of measuring adaptive immunity | |
| JP5026047B2 (ja) | 自己免疫疾患の発症に関わる自己応答性ｔ細胞またはｔ細胞受容体の同定方法、およびその利用 | |
| WO2015134787A2 (en) | Methods using randomer-containing synthetic molecules | |
| KR20180054829A (ko) | 면역 레퍼토리 정상성 평가 방법 및 그 용도 | |
| JP2014503223A (ja) | 免疫多様性の評価方法およびその使用 | |
| US20220088174A1 (en) | Genomic variants in ig gene regions and uses of same | |
| KR20170134432A (ko) | 개체의 면역 레퍼토리에서의 변화를 측정하는 방법 | |
| Zhu et al. | The multilevel extensive diversity across the cynomolgus macaque captured by ultra-deep adaptive immune receptor repertoire sequencing | |
| Yang et al. | Large-scale Analysis of 2,152 dataset reveals key features of B cell biology and the antibody repertoire | |
| Van Horebeek et al. | Somatic mosaicism in multiple sclerosis: Detection and insights into disease | |
| HK1212735B (zh) | 用於评估免疫组库的方法 | |
| Gibson | Characterization of the immunoglobulin lambda chain across diverse human populations. | |
| Ford | Uncovering the hidden diversity of antibody heavy chains and their implications for autoantibody mediated disease. | |
| Rosati | The T-cell receptor repertoire in inflammatory bowel diseases | |
| US20180051336A1 (en) | Methods for diagnosing multiple sclerosis using vh4 antibody genes | |
| Kim | Applications of high throughput sequencing for immunology and clinical diagnostics | |
| Miri Michaeli et al. | frontiers in METHODS ARTICLE IMMUNOLOGY |